Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Launches Reformulated Dexatrim To Revitalize Declining Brand

This article was originally published in The Tan Sheet

Executive Summary

Chattem expects to boost sales of its Dexatrim weight-loss brand and compete with category leader alli by launching a reformulated line extension carrying expanded claims

You may also be interested in...



New Products In Brief

VimVida tries fresh take on vitamins; Halo spray pitched as germ shield; Zarbee’s extends cough remedies into extra-strength; Nutrigold launches 7-keto for weight loss; NP Nutra adds kale greens ingredient line; Rivalus debuts clean workout powder; more New Products In Brief.

New Products In Brief

VimVida tries fresh take on vitamins; Halo spray pitched as germ shield; Zarbee’s extends cough remedies into extra-strength; Nutrigold launches 7-keto for weight loss; NP Nutra adds kale greens ingredient line; Rivalus debuts clean workout powder; more New Products In Brief.

Chattem Launching ACT, Icy Hot Line Extensions, Raises Guidance

Chattem says planned launches of line extensions for ACT,Icy Hot and other products in part prompted it to set its fiscal 2009 guidance at 60 cents to 75 cents per share above its 2008 guidance

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel